Topics:

UFT/Leucovorin: An ‘Excellent Alternative’ to 5-FU/Leucovorin in Colorectal Cancer

UFT/Leucovorin: An ‘Excellent Alternative’ to 5-FU/Leucovorin in Colorectal Cancer

NEW YORK-The combination of UFT (an oral fluoropyrimidine consisting of tegafur plus uracil) and leucovorin "is tolerable and efficacious" and "an excellent alternative to fluorouracil/leucovorin, according to the results of a phase II multicenter trial (abstract 3608). "Prolonged administration of UFT/leucovorin has a similar toxicity profile to infusional 5- FU," the investigators concluded. They also noted that UFT/leucovorin "compares favorably with other oral fluoropyrimidines" and saw "no disadvantage in treating the very elderly" (older than age 75). The principal toxicities were diarrhea and neutropenia. Grade 3/4 diarrhea occurred in 23% of patients and grade 3/4 neutropenia, in 5%. Other toxicities included fatigue in 14.3% and nausea (but no grade 4 events) in 10.7%. No cases of hand-foot syndrome were observed. Treatment Every 8 Hours A total of 58 patients were enrolled in the Eastern Cooperative Oncology Group (ECOG) study 1299. The median age of patients was 81 years (range 75-90 years). Performance status was 0 for 14 patients (24%), 1 for 31 patients (56%), and 2 for 13 patients (20%). Patients had undergone no prior chemotherapy for metastatic disease, but 13 patients had undergone prior adjuvant chemotherapy. Treatment was administered as UFT (300 mg/m2) plus leucovorin (30 mg) every 8 hours for 28 days, with 7 days of rest. CT scans were performed every 2 weeks. Similar Results to Single-Agent 5-FU According to updated data presented by Elizabeta C. Popa, MD, of New York University Cancer Institute, the best confirmed responses among the 55 treated patients were a complete response in 1 patient and a partial response in 11 patients. Eighteen patients had stable disease and 16 had progressive disease. Nine patients were not evaluable (Table 1). Results are similar to the 22% response rate and 13-month median survival reported for single-agent 5-FU. "Phase III studies comparing bolus IV 5-FU and oral UFT/leucovorin have shown similar response rates and survival outcomes to our study," Dr. Popa added. The investigators said that additional studies comparing infusional 5- FU with oral UFT/leucovorin, as well as phase II studies using UFT/leucovorin in combination with newer agents, such as oxaliplatin (Eloxatin), irinotecan (Camptosar), and biologics, "are warranted to establish maximal utility of this oral fluoropyrimidine."

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.